What is Semaglutide 1.7 mg FlexTouch Pen?
The Semaglutide 1.7 mg FlexTouch Pen is a prescription medication designed to support weight loss and maintenance in overweight or obese adults. Manufactured by Novo Nordisk India, this medication combines advanced pharmaceutical technology with the active ingredient semaglutide to help manage body weight effectively.
This injectable pen delivers a precise dose of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It is intended to be used as part of a comprehensive weight management plan that includes diet and exercise, providing an important option for adults struggling with weight-related health issues.
Uses of Semaglutide 1.7 mg FlexTouch Pen
- Weight loss and maintenance for overweight adults
- Treatment of obesity in adults with a body mass index (BMI) indicative of overweight or obesity
- Assisting in reducing weight-related health risks when combined with lifestyle changes
How Semaglutide 1.7 mg FlexTouch Pen Works
Semaglutide works by mimicking the effects of the natural hormone GLP-1, which targets areas of the brain involved in appetite regulation. This reduces feelings of hunger and helps control portion sizes, aiding patients in consuming fewer calories. Additionally, semaglutide slows gastric emptying, prolonging the sensation of fullness after meals.
By influencing these processes, the Semaglutide 1.7 mg FlexTouch Pen helps patients adhere to a reduced-calorie diet more easily, promoting progressive and sustained weight loss over time.
Benefits of Semaglutide 1.7 mg FlexTouch Pen
- Supports significant weight reduction when combined with diet and exercise
- Helps maintain weight loss over the long term
- Improves control over hunger and appetite
- May reduce risk factors associated with obesity-related conditions
- Convenient once-weekly injectable pen
Dosage and Administration
The Semaglutide 1.7 mg FlexTouch Pen is typically administered once weekly by subcutaneous injection. The dosage is adjusted gradually based on individual response to minimize side effects and optimize outcomes.
It is important to follow the healthcare provider's instructions carefully. The injection site can be the thigh, abdomen, or upper arm, rotating sites with each dose to reduce irritation. Patients should be trained on how to use the FlexTouch Pen properly before starting treatment.
Who Should Use Semaglutide 1.7 mg FlexTouch Pen?
This medication is intended for adults who are overweight or obese and have struggled to achieve weight loss through diet and exercise alone. It is especially suitable for those who have weight-related health risks and can benefit from medically supported weight management.
Who Should Avoid Semaglutide 1.7 mg FlexTouch Pen?
Semaglutide should not be used by individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It is also contraindicated in patients with hypersensitivity to semaglutide or any components of the formulation.
Pregnant or breastfeeding women and children should avoid using this medication. Patients with severe gastrointestinal disease or diabetic ketoacidosis should consult a healthcare professional before use.
Side Effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Headache
- Fatigue
- Dizziness
- Injection site reactions including redness and irritation
Safety Advice
- Inform your doctor about all medical conditions before starting treatment
- Do not use if allergic to semaglutide or any other ingredients
- Monitor blood sugar if diabetic as dosage adjustments may be necessary
- Avoid alcohol as it may affect blood sugar and increase side effects
- Store the pen according to instructions to preserve medication effectiveness
- Seek immediate medical attention if symptoms of allergic reaction occur
Drug Interactions
- May interact with insulin and other diabetes medications
- Possible interactions with oral contraceptives
- May alter the effectiveness of certain blood pressure medications
- Caution advised when taken with medications affecting gastric motility
Storage Instructions
Store the Semaglutide 1.7 mg FlexTouch Pen in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light and keep the pen in its original packaging until use. Once in use, the pen can be stored at room temperature (up to 30°C) for up to 6 weeks. Dispose of the pen safely after all doses are administered or after expiration.
Where to buy Semaglutide 1.7 mg FlexTouch Pen in Canada?
The Semaglutide 1.7 mg FlexTouch Pen is available at licensed pharmacies throughout Canada. It requires a prescription from a qualified healthcare provider. Patients are advised to purchase from reputable pharmacies to ensure authenticity and proper handling. Online pharmacies with Canadian certification may also stock this medication under proper regulatory compliance.
Frequently Asked Questions (FAQ)
Is Semaglutide 1.7 mg FlexTouch Pen available in Canada?
Yes, it is available in Canada through licensed pharmacies with a valid prescription.
What is the price of Semaglutide 1.7 mg FlexTouch Pen in Canada?
Pricing varies based on pharmacy and insurance coverage; it is recommended to check with local pharmacies or health insurance providers.
What happens if I miss a dose?
If a dose is missed, inject as soon as possible within 5 days after the missed dose. If more than 5 days have passed, skip the missed dose and take the next dose on the regular schedule.
Where can I find Semaglutide 1.7 mg FlexTouch Pen for sale?
It can be found at licensed pharmacies in Canada or through authorized online pharmacy services with a prescription.
How should I store the Semaglutide FlexTouch Pen?
Store unused pens in the refrigerator and avoid freezing. Once opened, pens can be kept at room temperature for up to 6 weeks.
Can I use Semaglutide if I am pregnant or breastfeeding?
Semaglutide is not recommended during pregnancy or breastfeeding. Consult your healthcare provider for alternatives.
Are there any common side effects I should watch for?
Common side effects include nausea, vomiting, diarrhea, and injection site reactions. Contact your doctor if side effects worsen or are persistent.
Conclusion
The Semaglutide 1.7 mg FlexTouch Pen by Novo Nordisk India offers a clinically supported approach to weight loss and weight maintenance in adults facing obesity or being overweight. With its targeted mechanism, ease of use, and added benefits, it represents a valuable option when combined with a healthy lifestyle. Patients should always use this medication under medical supervision, adhering to prescribed dosing and safety guidelines for optimal outcomes.
Leave A Review